MYL(600993)2022-04-26 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥949,086,965.18, representing a year-on-year increase of 10.24%[5] - The net profit attributable to shareholders for Q1 2022 was ¥137,549,555.60, reflecting a growth of 17.30% compared to the same period last year[5] - The basic earnings per share for Q1 2022 was ¥0.32, an increase of 18.52% year-on-year[5] - Operating profit for Q1 2022 was ¥157,904,799.33, compared to ¥141,931,707.20 in Q1 2021, reflecting a growth of 11.3%[33] - The total comprehensive income for Q1 2022 was ¥137,227,004.46, compared to ¥118,173,435.47 in Q1 2021, marking an increase of 16.1%[34] - Net profit for Q1 2022 reached ¥144,892,354.29, compared to ¥134,728,011.10 in Q1 2021, reflecting a growth of approximately 7.9%[52] Assets and Liabilities - Total assets at the end of Q1 2022 reached ¥4,288,232,363.28, up 3.91% from the end of the previous year[8] - The total liabilities of the company as of March 31, 2022, were ¥834,796,410.85, compared to ¥812,721,320.88 at the end of 2021[28] - The company's total liabilities increased to ¥594,314,516.32 as of March 31, 2022, from ¥479,848,467.26 as of December 31, 2021, marking an increase of approximately 24.0%[47] - The company's total equity increased to ¥3,453,435,952.43 from ¥3,314,199,313.16, marking an increase of approximately 4.2%[28] - The total equity increased to ¥3,397,520,187.53 as of March 31, 2022, from ¥3,252,627,833.24 as of December 31, 2021, representing a growth of about 4.5%[47] Cash Flow - The company reported a net cash flow from operating activities of -¥137,319,701.64, which is not applicable for year-on-year comparison[5] - The company reported a net cash outflow from operating activities of ¥137,319,701.64, compared to an outflow of ¥119,998,544.41 in the previous year[38] - In Q1 2022, the net cash flow from operating activities was 59,275,783.61 in Q1 2021[57] - Total cash inflow from operating activities was 418,740,027.64 in the same period last year, reflecting a year-over-year increase of approximately 21.8%[57] - Cash outflow from operating activities decreased to 478,015,811.25, marking a reduction of about 12.7%[57] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 54,895[14] - Shareholders' equity attributable to the parent company increased to ¥3,308,828,728.32, marking a 4.33% rise from the previous year-end[8] Research and Development - Research and development expenses increased to ¥17,671,619.69, a rise of 19.8% from ¥14,730,343.51 in Q1 2021[33] - Research and development expenses for Q1 2022 were ¥15,315,072.34, compared to ¥13,373,147.98 in Q1 2021, showing an increase of about 14.5%[50] Inventory and Receivables - Accounts receivable rose by 190.11%, primarily due to increased sales in the pharmaceutical commercial sector[10] - Accounts receivable increased significantly to ¥358,106,797.81 from ¥123,437,725.21, representing a growth of about 189.5%[23] - The company reported a decrease in inventory to ¥275,451,884.25 from ¥313,924,961.87, a decline of about 12.2%[23] Financial Position - The company's cash and cash equivalents decreased to ¥1,841,142,684.53 from ¥2,430,562,506.25, reflecting a decline of approximately 24.3%[23] - The company's cash and cash equivalents decreased to ¥1,692,323,598.99 as of March 31, 2022, from ¥2,056,690,921.93 as of December 31, 2021, a decline of approximately 17.7%[47] - Cash and cash equivalents at the end of Q1 2022 totaled ¥1,810,245,651.96, an increase from ¥1,224,751,560.94 at the end of Q1 2021[41] Other Financial Metrics - The weighted average return on equity for Q1 2022 was 4.25%, an increase of 0.21 percentage points[5] - The company experienced a significant increase in trading financial assets by 358.09% due to the purchase of wealth management products[10] - The company experienced a decrease in financial expenses, reporting a net financial income of ¥10,729,185.03 compared to a loss of ¥8,583,945.87 in the previous year[33] - The company reported a decrease in sales expenses to ¥84,241,385.63 in Q1 2022 from ¥95,099,458.28 in Q1 2021, a reduction of approximately 11.5%[50]